KDR and breast cancer: By combining the VEGF-decreasing activity with the VEGFR activation inhibition, CORMs can also help in the reduction of the dosage for existing anti-angiogenic drugs or lead to the reuse of revoked drugs for breast cancer, such as Avastin due to the non-significant improvement of patient survival and several side effects [55–57].